Last Update: Nov 25, 2024
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)
ClinicalTrials.gov Identifier:
Novartis Reference Number:CAAA617D12302
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu)
vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer
(OMPC) progressing after definitive therapy to their primary tumor. The data generated
from this study will provide evidence for the treatment of AAA617 in early-stage prostate
cancer patients to control recurrent tumor from progressing to fatal metastatic disease
while preserving quality of life by delaying treatment with androgen deprivation therapy
(ADT). All participants will be assessed for eligibility and will undergo baseline disease
assessments including a mandatory gallium (68Ga) gozetotide (also known as
[68Ga]Ga-PSMA-11) or piflufolastat (18F) ( also known as[18F]DCFPyL) PET/CT scan and
conventional imaging (i.e., CT/MRI and bone scans).

Piflufolastat (18F) PET/CT scan will be performed in countries where it is approved.

Stereotactic Body Radiation Therapy (SBRT) will be administered to all metastatic
Prostate Cancer (PC) lesions after randomization and before the start of treatment with
AAA617 or observation.

- The duration of SBRT procedures is approximately 3 weeks.

- For participants randomized to the investigational arm (AAA617), the treatment
duration will be up to 4 cycles of AAA617. For participants randomized to the
control arm (observation) the treatment duration will end at the last fraction of
SBRT administration.

- The visit frequency will be every week 1 and 3 of each of the 4 cycles and every 16
weeks thereafter (for both arms) until first event of disease progression (RECIST
1.1)

- The study duration is approximately 6.5 years.

Oligometastatic Prostate Cancer (OMPC)
Phase3
Recruiting
450
Mar 12, 2024
Jul 09, 2030
Male
18 Years - (Adult, Older Adult)

Interventions

Drug

AAA617

Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm

Eligibility Criteria

Key Inclusion criteria:

1. Histologically confirmed prostate cancer prior to randomization

2. Participants must have biochemically recurrent disease after definitive treatment to
prostate by Radical Prostatectomy ((RP), (alone or with post-operative radiation to
prostate bed/pelvic nodes)) or External beam Radiation Therapy (XRT), (prostate
alone or prostate with seminal vesicle and/or pelvic nodes) and/or brachytherapy
prior to randomization. Biochemical recurrence is defined as: nadir PSA + 2 ng/mL
post XRT (if participant received-radiation therapy to intact prostate) and PSA >
0.2 ng/mL and rising post RP (with or without post-operation Radiation Therapy (RT))

3. Participants must have OMPC with =< 5 PSMA-positive metastatic lesions on screening
PSMA PET/CT scan (with either gallium (68Ga) gozetotide or piflufolastat (18F)) as
visually assessed by BIRC based on the methodology proposed in the Prostate Cancer
Molecular Imaging Standardized Evaluation (PROMISE v2) (Seifert et al 2023); for
further details, please refer to Section 8.1 and the Imaging Manual. Metastatic
lesions may include regional/pelvic lymph nodes (N1), distant lymph nodes (M1a),
bone (M1b), lung and others visceral (M1c) except liver and brain classified using
AJCC 8. When counting the number of oligometastatic lesions, each lesion is counted
as distinct metastasis irrespective of its anatomical location (e.g., one pelvic and
one extra-pelvic lymph node will be counted as two metastatic lesions)

4. At least 1 PSMA-positive lesion should be a distant metastasis (M1) per AJCC8
classification at screening. For AJCC M staging, PSMA PET information should be used

5. Participants must have a negative conventional imaging for M1 disease at screening.

Note:

- For a participant not to be eligible, CI positive M1 lesions should be
unequivocal in CI scans, i.e., potentially not attributable to findings thought
to represent something other than tumor (e.g., degenerative, or post-traumatic
changes or Paget's disease in bone lesions). For conventional imaging
assessments, bone lesions must be assessed by bone scan only and soft tissue
lesions must be assessed by CT/MRI scans only at screening.

- Prior knowledge of PSMA PET positivity should not influence the radiologist
(reader) in determination of CI positivity. Two different readers will be
involved, one reader for PSMA PET scan and one reader for CI: Reader will be
blinded to PSMA PET scan results while reading CI scans. Reader should not
modify their assessment of CI scans (e.g. changing a lesion previously
identified as equivocal in CI to unequivocal) after reading the PSMA PET scan.
Similarly, biopsy positivity should not influence the reader in the assessment
of CI positivity. More details on the reading paradigm will be provided in the
imaging charter

- MRI for radiation treatment planning may show M1 disease but this will not
exclude the participant from the study if the lesion is deemed negative per
baseline CT or bone scans

- Participants with pelvic disease (N1) seen in conventional imaging are allowed
if the local spread is below common iliac bifurcation (per AJCC 8 definition of
local disease)

- Distant lymph node disease (M1a) that is visible per CI and less than 10mm in
the short axis is not exclusionary irrespective of PSMA PET positivity.

- If a previously surgically removed lesion was unequivocal for M1 by bone scan
or CT, the participant is not eligible.

6. All metastatic lesions detected at screening should be amenable to SBRT

7. Non-castration testosterone level >100 ng/dL at screening

Key Exclusion criteria:

1. Participants with de novo OMPC at screening

2. Unmanageable concurrent bladder outflow obstruction or urinary incontinence at
screening. Note: participants with bladder outflow obstruction or urinary
incontinence, which is manageable and controlled with best available standard of
care (incl. pads, drainage) are allowed

3. Prior therapy with:

1. ADT including bilateral orchiectomy

- Participants who had XRT or RP and completed adjuvant ADT (or ADT+ARPI)
prior to recurrence are eligible to participate if the last dose of ADT
(or ADT+ARPI) was before 12 months from randomization. Participants who
had prior SBRT with short term ADT (3-6 months) are also allowed if the
ADT was stopped at least 12 months before randomization.

- Participants who discontinued ADT due to disease progression are not
allowed (i.e., Castration-Resistant Prostate Cancer (CRPC) participants)

2. Other hormonal therapy. e.g.,

- Use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride),
other steroidogenesis inhibitors (aminoglutethimide) if used in the
context of prostate cancer treatment. Same medications are allowed if used
for other indications: e.g., Benign Prostatic Hyperplasia (BPH), if
stopped at least 5 half-lives before randomization.

- First-generation anti-androgens (bicalutamide, flutamide, nilutamide,
cyproterone)

- Second generation anti-androgens (e.g., enzalutamide, apalutamide and
darolutamide)

- CYP17 inhibitors (e.g., abiraterone acetate, orteronel, galeterone,
ketoconazole). Short term ketoconazole treatment (<28 days) is permitted

3. Radiopharmaceutical agents (e.g., Strontium-89, PSMA-targeted radioligand
therapy)

4. Immunotherapy (e.g., sipuleucel-T)

5. Chemotherapy, except if administered in the adjuvant/neoadjuvant setting
completed > 12 months before randomization

6. Any other investigational or systemic agents for metastatic disease

4. Radiation therapy external beam radiation therapy (EBRT) and brachytherapy within 28
days before randomization

5. Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, hormonal
therapy (see ADT initiation guidance in Section 6.8.2), Poly Adenosine
Diphosphate-Ribose Polymerase (PARP) inhibitor, biological therapy or
investigational therapy

6. Diagnosed at screening with other malignancies that are expected to alter life
expectancy or may interfere with disease assessment. However, participants with a
prior history of malignancy that has been adequately treated and who have been
disease/treatment free for more than 3 years are eligible, as are participants with
adequately treated non-melanoma skin cancer and superficial bladder cancer.

7. History or current diagnosis of ECG abnormalities indicating significant risk of
safety for participants participating in the study such as:

- Concomitant clinically significant cardiac arrhythmias, e.g. sustained
ventricular tachycardia, and clinically significant second or third degree
Atrioventricular (AV) block without a pacemaker

- History of familial long QT syndrome or known family history of Torsades de
Pointe

8. Participants in immediate need of ADT as assessed by the investigator.

Other protocol defined Inclusion/Exclusion may apply.

Novartis Investigative Site

Recruiting

Adelaide,South Australia,5000,Australia

Novartis Investigative Site

Recruiting

Malvern,Victoria,3144,Australia

Novartis Investigative Site

Recruiting

Darlinghurst,New South Wales,2010,Australia

Novartis Investigative Site

Recruiting

Wien,1090,Austria

Novartis Investigative Site

Recruiting

Gent,9000,Belgium

Novartis Investigative Site

Recruiting

Wilrijk,2610,Belgium

Novartis Investigative Site

Recruiting

Montreal,Quebec,H3t 1e2,Canada

Novartis Investigative Site

Recruiting

Quebec,G1j 1z4,Canada

Novartis Investigative Site

Recruiting

Montreal,Quebec,H2x 1r9,Canada

Novartis Investigative Site

Recruiting

Olomouc,CZE,779 00,Czechia

Novartis Investigative Site

Recruiting

Ostrava,Poruba,708 52,Czechia

Novartis Investigative Site

Recruiting

Praha 5,150 06,Czechia

Novartis Investigative Site

Recruiting

Bron,69677,France

Novartis Investigative Site

Recruiting

Clermont-Ferrand,63011,France

Novartis Investigative Site

Recruiting

Rouen,76038,France

Novartis Investigative Site

Recruiting

Saint Herblain,44805,France

Novartis Investigative Site

Recruiting

Saint-Cloud,Hauts De Seine,92210,France

Novartis Investigative Site

Recruiting

Bordeaux,33076,France

Novartis Investigative Site

Recruiting

Debrecen,4032,Hungary

Novartis Investigative Site

Recruiting

Haifa,3109601,Israel

Novartis Investigative Site

Recruiting

Jerusalem,9112001,Israel

Novartis Investigative Site

Recruiting

Petach Tikva,4941492,Israel

Novartis Investigative Site

Recruiting

Tel Aviv,6423906,Israel

Novartis Investigative Site

Recruiting

Beer Sheva,8457108,Israel

Novartis Investigative Site

Recruiting

Milano,MI,20141,Italy

Novartis Investigative Site

Recruiting

Fukuoka city,Fukuoka,812-8582,Japan

Novartis Investigative Site

Recruiting

Fukuoka,812-0033,Japan

Novartis Investigative Site

Recruiting

Fukushima city,Fukushima,960 1295,Japan

Novartis Investigative Site

Recruiting

Kyoto,606 8507,Japan

Novartis Investigative Site

Recruiting

Sapporo city,Hokkaido,060 8648,Japan

Novartis Investigative Site

Recruiting

Kobe,Hyogo,650-0047,Japan

Novartis Investigative Site

Recruiting

Kanazawa,Ishikawa,920 8641,Japan

Novartis Investigative Site

Recruiting

Yokohama-city,Kanagawa,236-0004,Japan

Novartis Investigative Site

Recruiting

Kashiwa,Chiba,277 8577,Japan

Novartis Investigative Site

Recruiting

Fukuoka,811-0213,Japan

Novartis Investigative Site

Recruiting

Singapore,119228,Singapore

Novartis Investigative Site

Recruiting

Singapore,168583,Singapore

Novartis Investigative Site

Recruiting

Bratislava,Slovak Republic,83310,Slovakia

Novartis Investigative Site

Recruiting

Kosice,041 91,Slovakia

Novartis Investigative Site

Recruiting

Granada,Andalucia,18014,Spain

Novartis Investigative Site

Recruiting

Sevilla,Andalucia,41013,Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08036,Spain

Novartis Investigative Site

Recruiting

Madrid,28041,Spain

Novartis Investigative Site

Recruiting

Valencia,Comunidad Valenciana,46010,Spain

Novartis Investigative Site

Recruiting

El Palmar,Murcia,30120,Spain

Novartis Investigative Site

Recruiting

Madrid,28040,Spain

Novartis Investigative Site

Recruiting

Geneve 14,1211,Switzerland

Novartis Investigative Site

Recruiting

Luzern,6006,Switzerland

Novartis Investigative Site

Recruiting

Taipei,11217,Taiwan

Novartis Investigative Site

Recruiting

Taoyuan,33305,Taiwan

Novartis Investigative Site

Recruiting

Taipei,103616,Taiwan

Cancer Specialists of North Florida

Recruiting

Jacksonville,Florida,32256,United States

Richard Cassidy
Ryan Veldhuizen

Dayton Physicians

Recruiting

Kettering,Ohio,45409,United States

Trevor Bluemel

BAMF Health

Recruiting

Grand Rapids,Michigan,49503,United States

Brandon Mancini
Jennifer Hoseth

Johns Hopkins Kimmel Com Cancer Ctr

Recruiting

Baltimore,Maryland,21231,United States

Ana Kiess

Oregon Urology Institute

Recruiting

Springfield,Oregon,97477,United States

Bryan Mehlhaff
Cordell Chase

Profound Research LLC

Recruiting

Royal Oak,Michigan,48073,United States

Adam Gadzinski
Catherine Maples

Highlands Oncology Group

Recruiting

Fayetteville,Arkansas,72703,United States

Joseph Thaddeus Beck
Stephanie Deboard

Wash U School of Medicine

Recruiting

Saint Louis,Missouri,63110,United States

Ellen Haennie
Hiram Gay

Carolina Urologic Research Center, LLC

Recruiting

Myrtle Beach,South Carolina,29572,United States

Kim Dannelly
Neal D Shore

Mayo Clinic Rochester

Recruiting

Rochester,Minnesota,55905,United States

Mathew Timm
Ryan Phillips

Rocky Mountain Cancer Centers

Recruiting

Longmont,Colorado,80501,United States

Allen Cohn
Meghan Ayers

Virginia Oncology Associates

Recruiting

Norfolk,Virginia,23502,United States

Mark Fleming
Wendi Gobhardt

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals